PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 50657-01404	FOR FURTHER see Form PCT/ISA/220 ACTION as well as, where applicable, item 5 below.				
International application No. PCT/US04/26508	International filing date (day/month/year) 13 August 2004 (13.08.2004)				
Applicant WYETH					
This international search report consists It is also accompanied					
Basis of the Report a. With regard to the language, the international search was carried out on the basis of:					
	application in the language in which it was file				
	a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b))				
b. With regard to any nucleoti	de and/or amino acid sequence disclosed in the	ne international application, see Box No. I.			
2. Certain claims were found	unsearchable (See Box No. II)				
3. Unity of invention is lacking4. With regard to the title,	g (See Box No. III)				
	itted by the applicant				
the text is approved as submitted by the applicant. the text has been established by this Authority to read as follows:					
. —	•				
		•			
•					
 With regard to the abstract, 					
the text is approved as subm	•				
the text has been established may, within one month from	, according to Rule 38.2(b), by this Authority a the date of mailing of this international search	is it appears in Box No. IV. The applicant report, submit comments to this Authority.			
6. With regard to the drawings,					
	oublished with the abstract is Figure No.	•			
as suggested by the					
<u></u>	authority, because the applicant failed to suggest	·			
b. none of the figures is to be p	authority, because this figure better characterize	es the invention.			
	orm PCT/ISA/210 (first sheet) (April 2005)				

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/26508

DUX INU	.1 [Autreotide and/or animo acid sequence(s) (Continuation of Reili 1-b of the first succe)
	egard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed tion, the international search was carried out on the basis of: type of material a sequence listing table(s) related to the sequence listing
b.	format of material on paper in electronic form
c.	time of filing/furnishing contained in the international application as filed filed together with the international application in electronic form furnished subsequently to this Authority for the purposes of search
2.	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.	Additional comments:

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/26508

Box No.	,			
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:			
2.	Claims Nos.: 20 and 21 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Please See Continuation Sheet			
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box No.	II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)			
This Intern	ational Searching Authority found multiple inventions in this international application, as follows:			
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.			
2.	As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees.			
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:			
•				
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1 and 19-21 to the extent that they read on SEQ ID NO: 9			
Remark or	Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.			
·	The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.			
orm PCT/IS	A/210 (continuation of first chart (2008) (Angil 2005)			

Form PCT/ISA/210 (continuation of first sheet(2)) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/26508

A. CLAS IPC(7)					
US CL					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELI	DS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) U.S.: 514/12, 54; 530/324; 930/20, DIG500					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) USPAT, USPGPUB, GENESEQ, UNIPROT, PIR. SEQ ID NO: 9 was the query.					
C. DOC	JMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where a		Relevant to claim No.		
Α	WO 95/23861 A1 (GU et al.) 08 September 1995 (08		1, 19		
Α	in Geneseq Protein Database, human megakaryocytopoientin protein, 94% sequence identity. WO 92/13075 A1 (TURNER et al.) 06 August 1992 (06.08.1992), see Result 7, sequence search in Geneseq Protein Database, human megakaryocyte stimulating factor, 94% sequence identity.				
Α	WO 00/64930 A2 (JAY) 02 November 2000 (02.11.2000), see Result 8, sequence search in Geneseq Protein Database, human megakaryocyte stimulating factor, 94% sequence identity.		1, 19		
	,				
		·			
	·				
Further	documents are listed in the continuation of Box C.	See patent family annex.			
* S ₁	pecial categories of cited documents:	"T" later document published after the inter			
"A" document particular	defining the general state of the art which is not considered to be of relevance	date and not in conflict with the applica principle or theory underlying the inven	ition		
"E" earlier app	olication or patent published on or after the international filing date	"X" document of particular relevance; the cl considered novel or cannot be considered when the document is taken alone			
	which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	"Y" document of particular relevance; the cl considered to involve an inventive step	when the document is		
"O" document	referring to an oral disclosure, use, exhibition or other means	combined with one or more other such being obvious to a person skilled in the			
	published prior to the international filing date but later than the ste claimed	"&" document member of the same patent family			
	Date of the actual completion of the international search Date of mailing of the international search report 22 NOV 2006		report		
	005 (17.10.2005)	Authorized officer	}		
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents		Rosanne Kosson	Egglson		
		Telephone No. 5/1-272-1600	(D)/L		
Facsimile No.	(571) 273-3201	•			

Form PCT/ISA/210 (second sheet) (April 2005)

INTERNATIONAL SEARCH REPORT	PCT/US04/26508
Continuation of Box II Reason 2:	
Claims 20-21 could not be searched because they are not supported by the specification provides no indication as to h	ication. These claims recite a therapeutically effective ow much of the protein of claim 19 is therapeutically
effective in any subject.	
	*
	•

International application No.

Form PCT/ISA/210 (extra sheet) (April 2005)